Prelude Therapeutics Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Prelude is a clinical-stage oncology company with no product revenue to date and reported no revenue in the quarter.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 or prior-period balance |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $21.8 million | $22.8 million |
| General and administrative expense | $7.3 million | $7.5 million |
| Total operating expenses | $29.1 million | $30.3 million |
| Net loss | $27.7 million | $29.5 million |
| Net loss per share, basic and diluted | $0.58 | $0.63 |
| Net cash used in operating activities | $30.1 million | $21.9 million |
| Cash, cash equivalents and marketable securities | $172.3 million | Not stated as a comparable total |
At March 31, 2023, cash and cash equivalents were $18.2 million and marketable securities were $154.1 million; restricted cash of $4.0 million is separate. Total assets were $198.3 million, total liabilities $23.0 million, and stockholders’ equity $175.3 million. The filing reports no credit facility or committed capital source. Liabilities include lease obligations and deferred state grant funds; the filing does not present these as conventional borrowings.
Changes versus the prior comparable period
- Operating expenses declined $1.2 million, with R&D down $1.0 million and G&A down $0.2 million. Management attributed the R&D decrease primarily to timing of clinical research programs.
- Net loss narrowed by $1.7 million, partly because other income rose by $0.6 million, primarily from interest earned on cash and investments.
- Operating cash use increased by $8.2 million. The company cited a $6.6 million increase in long-term prepaid expenses and other long-term assets as a significant cash-flow item.
- Marketable securities fell from $171.1 million at year-end 2022 to $154.1 million at quarter-end; cash and cash equivalents fell from $30.6 million to $18.2 million.
- PRMT5 program expense declined to $0.4 million from $3.3 million, following the company’s decision to discontinue internal development of its two PRMT5 clinical candidates and focus resources on other programs.
Outlook, programs and risks
- Management believes available cash, cash equivalents and marketable securities will fund operating expenses and capital expenditures into the fourth quarter of 2024. This estimate depends on assumptions that may prove imprecise; additional financing will be needed thereafter, and may not be available on acceptable terms or at all.
- The company expects significant continuing expenses and losses and does not expect product sales revenue in the foreseeable future. It may seek equity or debt financing, collaborations, strategic alliances or licensing arrangements; equity financing could dilute holders, while partnerships could require giving up valuable rights.
- Management expects R&D expense to increase over the coming years as clinical programs advance. It also expects G&A expense to rise to support operations and possible commercialization.
- At an April 2023 scientific meeting, the company reported PRT2527 was generally well tolerated in the Phase 1 study and selected a 15 mg/m² weekly dose for further evaluation. It expected to present a recommended Phase 2 dose for hematologic malignancies in the second half of 2023.
- For PRT1419, management reported acceptable safety and tolerability at studied doses, but no tumor reductions met response criteria. Further evaluation in hematologic malignancies was ongoing, with a recommended Phase 2 dose targeted for the second half of 2023.
- Phase 1 studies of PRT3645 and PRT3789 were ongoing; an update on PRT3645 dose escalation was expected by year-end 2023. These are development plans and reported clinical observations, not assurances of efficacy or approval.
- Key risks include clinical and regulatory uncertainty, competition, intellectual-property protection, reliance on personnel and external research organizations, inflation-related cost pressures, and the need for additional capital. The company reported no material change to the risk factors in its 2022 Form 10-K and no material litigation then pending.
Important facts for investors to verify
- Whether cash burn and trial spending remain consistent with management’s stated runway through Q4 2024.
- Upcoming clinical data, dose-escalation progress and milestones for PRT2527, PRT1419, PRT3645 and PRT3789, including whether reported safety and activity support further development.
- The terms and any use of the March 2023 open-market sale agreement with Jefferies, including potential share issuance and dilution; the supplied filing text does not state sales under the agreement.
- Timing and amount of future financing, and any resulting dilution, debt restrictions or licensing of program rights.
- Lease-related commitments for the planned Chestnut Run premises, including $6.5 million of prepaid rent at quarter-end and the anticipated long-term rent schedule.